Truecaller’s Q4 results align with its preliminary figures, highlighted by a significant margin beat...
* Q4 EBIT of SEK 11m, way below expectations driven by a SEK 151 impairment * Underlying Corporate F...
After a year marked by both progress and setbacks, Xspray enters a pivotal 2026, with two upcoming P...
* EBIT SEK 2m vs FactSet consensus 12m * Sales declined 9% in USD terms, and DPS cut to SEK 2 (8) * ...
Redeye comments on G5’s Q4-resulst which were weaker than expected driven by a soft topline, partly ...
G5's Q4 report looks soft, driven by 5% weaker-than-expected top line which filters through to earni...
Redeye updates on Invisio after Q4-results which was much stronger than expected.
Redeye returns with an update following a softer-than-expected Q4 report.
The most interesting aspect of the Q4 2025 earnings release came on 29 January, when Scanfil publish...
Adjusted EBITA was slightly weaker than we expected in Q4.
* Q4 Paper EBIT of ~PLN 25m * Lower wood costs ahead, but markets still soft * Fair value range of S...
* Q4e: Sales of EUR 37m (45m), EBIT of EUR 0.7m (3.
Cell Impact avslutade 2025 med låg omsättning och ett fortsatt negativt rörelseresultat i en svag vä...
Redeye comments on Mendus’ Q4 report. We have updated our valuation scenarios and present a new base...
Aspo’s EUR 8.9m Q4 comparable EBITA landed clearly below our EUR 12.
Redeye returns with an update following Alligator Bioscience’s Q4 earnings release.
ByggPartner Gruppen avslutade 2025 starkt med 13 procent omsättningstillväxt och 74 procent högre or...
* Substantial margin-driven EBITA beat * We raise EBITA by 6-5% for '26e-'27e * Balance sheet soon s...
Redeye comments on Nitro Games Q4-results which where stronger-than-expected, driven by solid profit...
* Lower sales than estimated in Q4 * The CEO is optimistic for 2026 after a difficult 2025 * Adjustm...